August 04, 2017
In Re: Epipen (Epinephrine Injection, USP) Marketing, Sales Practices and Antitrust Litigation
Case Number:
2:17-md-02785
Court:
Nature of Suit:
Multi Party Litigation:
Class Action, Multi-district Litigation
Judge:
Firms
- Barnow & Associates
- Baron & Budd
- Barton & Burrows
- Beasley Allen
- Berkowitz Oliver
- Berman Tabacco
- Blood Hurst
- Boies Schiller
- Bradford & Wilson
- Burns Charest
- Bush Seyferth
- Butler Prather
- Carella Byrne
- Clark Hill
- DiCello Levitt
- Dollar Burns
- Foley & Lardner
- Foulston Siefkin
- Fredrikson & Byron
- Freshfields
- Gibbons PC
- Gibbs Law Group
- Gibson Dunn
- GM Law PC
- Goldman Scarlato
- Goodwin Procter
- Groom Law Group
- Gustafson Gluek
- Hagens Berman
- Hinkle Law Firm
- Hogan Lovells
- Holland & Knight
- Horn Aylward
- Joseph Saveri Law Firm
- Kaufman & Canoles
- Keller Rohrback
- King & Spalding
- Kramer Levin
- Lanier Law Firm
- Latham & Watkins
- Lathrop GPM
- Law Offices of Ursula Taylor
- Levi & Korsinsky
- Lightfoot Franklin
- Lockridge Grindal
- Lowey Dannenberg
- Marion's Inn
- Matthew G. Miller PC
- Mayer Brown
- McCune Wright
- Mehri & Skalet
- Pallas Partners
- Parker Waichman
- Perkins Coie
- Pritzker Levine
- Reed Smith
- Robbins Geller
- Robbins Russell
- Robins Kaplan
- Saiber LLC
- Scott&Scott
- Sharp Law LLP
- Shook Hardy
- Sidley Austin
- Siegfried & Jensen
- Spencer Fane
- Spragens Law
- Squitieri & Fearon
- Steven Williams Law
- Strategic Health Law
- Wagstaff & Cartmell
- Weil Gotshal
- White & Case
- Williams & Connolly
- Willkie Farr
- Wilson Sonsini
- Yarmuth LLP
Companies
- Aetna Inc.
- Amerigroup Corp.
- Centene Corp.
- Change Healthcare Inc.
- Coventry Health Care Inc.
- CVS Health Corp.
- Express Scripts Holding Co.
- Humana Inc.
- King Pharmaceuticals Inc.
- MedImpact Healthcare Systems Inc.
- Meridian Medical Technologies Inc.
- Optum Inc.
- OptumRx Inc.
- Pfizer Inc.
- Sanofi
- Teva Pharmaceutical Industries Ltd.
- The Segal Co. Inc.
- UnitedHealth Group Inc.
- Viatris Inc.
Sectors & Industries:
View recent docket activity
Reflects complaints, answers, motions, orders and trial notes entered from Jan. 1, 2011.
Additional or older documents may be available in Pacer.
Coverage
-
March 14, 2022
Judge OKs $264M Deal Ending Mylan EpiPen Price-Hike Suit
A Kansas federal court has preliminarily approved a $264 million deal that would end claims that Mylan colluded with Pfizer Inc. to obstruct generic versions of the EpiPen, the emergency drug used to treat severe allergic reactions, from entering the market.
Parties
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
- Direct access to case information and documents.
- All significant new filings across U.S. federal district courts, updated hourly on business days.
- Full-text searches on all patent complaints in federal courts.
- No-fee downloads of the complaints and so much more!
TRY LAW360 FREE FOR SEVEN DAYS
Already a subscriber? Click here to login